Package Leaflet: Information for the User
Maraviroc Tarbis 150 mg film-coated tablets EFG
Maraviroc Tarbis 300 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Maraviroc contains the active substance maraviroc. Maraviroc belongs to a group of medicines called CCR5 antagonists. Maraviroc works by blocking the CCR5 receptor, which the HIV virus uses to enter and infect blood cells.
Maraviroc is used to treat HIV-1 infection in adults, adolescents, and children aged 2 years and older, weighing at least 10 kg.
Maraviroc must be taken in combination with other medicines that are also used to treat HIV infection. All these medicines are called anti-HIV medicines or antiretrovirals.
Maraviroc, as part of combination therapy, reduces the amount of virus in your body and keeps it at a low level. This helps your body to increase the number of CD4 cells in the blood. CD4 cells are a type of white blood cell that are important for helping your body to fight infections.
Do not take Maraviroc Tarbis
Consult your doctorif you think this applies to you or your child.
Warnings and precautions
Talk to your doctor or pharmacist before taking or administering maraviroc.
Your doctor should take blood samples to see if maraviroc is a suitable treatment for you (or your child, if they are the patient).
Some people who take maraviroc have developed severe allergic reactions or skin reactions (see also “Severe side effects” in section 4).
Before taking this medicine, make sure your doctor knows if you (or your child) have or have had any of the following problems:
Tell your doctorbefore starting treatment if you think any of the above situations apply to you (or your child).
Conditions to be aware of
Some people who take medicines for HIV infection develop other conditions, which can be severe. These include:
You need to know what important signs and symptoms to look out for while taking maraviroc.
Read the information on “Other possible side effects of combination antiretroviral therapy for HIV” in section 4 of this leaflet.
Elderly patients
Only a limited number of people aged 65 years or older have taken maraviroc. If you belong to this age group, consult your doctor to see if you can take maraviroc.
Children
The use of maraviroc has not been tested in children under 2 years of age or weighing less than 10 kg. Therefore, maraviroc is not recommended in children under 2 years of age or weighing less than 10 kg.
Other medicines and Maraviroc Tarbis
Tell your doctor or pharmacist if you (or your child) are taking, have recently taken, or might take any other medicines.
Tell your doctor or pharmacist if you (or your child) start taking a new medicine while taking maraviroc.
It is likely that medicines containing St. John's Wort (Hypericum perforatum)will stop maraviroc from working properly. Do not take it while you are taking maraviroc.
Some medicines may affect the levels of maraviroc in the body when taken at the same time as maraviroc. These include:
Tell your doctorif you (or your child) are taking any of these medicines. This will allow your doctor to prescribe the correct dose of maraviroc.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby:
Ask your doctorabout the risks and benefits of taking maraviroc.
It is not recommendedthat HIV-infected women breastfeed their babies because HIV infection can be passed on to the baby through breast milk.
It is not known whether the components of maraviroc can pass into breast milk. If you are breastfeeding or thinking of breastfeeding, consult your doctor as soon as possible.
Driving and using machines
Maraviroc may make you feel dizzy.
Do not drive, ride a bike, or use machines or toolsif you are not sure that maraviroc does not affect you.
Maraviroc Tarbis contains soy lecithin.
Do not take this medicine if you are allergic to peanuts or soy.
Maraviroc Tarbis contains sodium.
Maraviroc contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
If you (or your child) are unable to swallow the tablets, your doctor will consider whether it is better for you (or your child) to take the oral solution of maraviroc.
How much to take
Adults
The recommended dose of maraviroc is 150 mg, 300 mg, or 600 mg twice a daydepending on whether you are taking other medicines at the same time. Always take the dose recommended by your doctor.
People with kidney problems
If you have kidney problems, your doctor may adjust your dose.
Consult your doctorif this applies to you.
Adolescents and children aged 2 years and over and weighing at least 10 kg
Your doctor will tell you the correct dose of maraviroc based on weight and other medicines being taken at the same time.
Maraviroc Tarbis can be taken with or without food.Maraviroc should always be taken orally.
Maraviroc must be taken in combination with other medicines used to treat HIV. Check the package leaflet of these other medicines to find out how to take them.
If you take or give more Maraviroc Tarbis than you should
If you accidentally take or give too much maraviroc
Contact your doctor or go to the nearest hospital immediately.
In case of overdose or accidental ingestion, consult your doctor or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take or give Maraviroc Tarbis
If you (or your child) miss a dose of maraviroc, take or give it as soon as possible and continue with the next dose at the usual time.
If it is almost time for the next dose, do not take or give the missed dose. Wait and take the next dose at the usual time.
Do not take or give a double dose to make up for a forgotten dose.
If you (or your child) stop taking Maraviroc Tarbis
Continue treatment with maraviroc until your doctor tells you to stop.
It is important that you take your medicines every day, as prescribed, to ensure that the HIV infection does not spread through your body. Therefore, unless your doctor tells you to stop treatment, it is important that you (or your child) continue treatment with maraviroc as described above.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, maraviroc can cause side effects, although not everybody gets them. Tell your doctor about any unusual changes that happen to you or your child.
Severe side effects - seek medical help immediately
Severe allergic reactions or skin reactions
Some people who took maraviroc have developed severe skin reactions and severe allergic reactions that can be life-threatening. These are rare and can affect up to 1 in 1,000 people who take maraviroc.
If you have any of these symptoms while being treated with maraviroc:
Contact your doctor immediatelyif you have these symptoms. Stop taking maraviroc.
Liver problems
These are rare and can affect up to 1 in 1,000 peoplewho take maraviroc. The signs include:
Contact a doctor immediatelyif you have these symptoms. Stop taking Maraviroc.
Other side effects
Common side effects
These can affect 1 to 10 in every 100 people:
Uncommon side effects
These can affect up to 1 in 100 people:
Rare side effects
These can affect up to 1 in 1,000 people:
Other possible side effects of combination antiretroviral therapy for HIV
People who take combination antiretroviral therapy for HIV may develop other side effects.
Symptoms of infection and inflammation
People with advanced HIV infection (AIDS) have a weakened immune system and are more likely to develop severe infections (opportunistic infections). After starting treatment, the immune system becomes stronger, so the body starts to fight these infections.
Symptoms of infection and inflammationcan develop, caused by:
Symptoms of autoimmune disorderscan appear many months after starting to take medicines for HIV infection. The symptoms can include:
If you have any symptoms of infection or if you notice any of the above symptoms:
Tell your doctor immediately.Do not take other medicines for infection without your doctor's advice.
Pain in the joints, stiffness, and bone problems
Some patients on combination antiretroviral therapy for HIV develop a condition called osteonecrosis. In this condition, parts of the bone tissue die due to a reduction in blood supply to the bones.
The frequency of this condition is not known. It is more likely to develop:
Signs to look out for include:
If you notice any of these symptoms:
Tell your doctor.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister/pack after EXP. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy for disposal.
Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Maraviroc Tarbis
The active ingredient is maraviroc.
Each film-coated tablet contains 150 mg of maraviroc.
Each film-coated tablet contains 300 mg of maraviroc.
The other components are:
Tablet core: Microcrystalline cellulose (E460), Sodium carboxymethyl starch (Type A), anhydrous colloidal silica, magnesium stearate (E470b), anhydrous calcium hydrogen phosphate (E341).
Coating: Poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171), macrogol (MW3350) (E1521), soybean lecithin (E322), indigo carmine (E132).
Appearance of the Product and Container Content
Maraviroc Tarbis 150 mg film-coated tablets EFG
Film-coated tablets, blue, oval, biconvex, with approximate dimensions 8.7 mm x 15.7 mm and engraved with "HM" on one side and "150" on the other.
Maraviroc Tarbis 300 mg film-coated tablets EFG
Film-coated tablets, blue, oval, biconvex, with approximate dimensions 19.4 mm x 10.7 mm and engraved with "HM" on one side and "300" on the other.
Maraviroc Tarbis is available in blisters containing 60 film-coated tablets and in single-dose perforated blisters containing 60 film-coated tablets.
HDPE bottles containing 60 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Tarbis Farma S.L.
Gran Vía Carlos III, 94
08028 Barcelona
Spain
Manufacturer
Amarox Pharma B.V.
Rouboslaan 32
Voorschoten, 2252TR
Netherlands
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Germany: Maraviroc Amarox 150 mg/300 mg Filmtabletten
Netherlands: Maraviroc Amarox 150 mg/300 mg, filmomhulde tabletten
Spain: Maraviroc Tarbis 150 mg/300 mg film-coated tablets EFG
Date of the last revision of this leaflet: 02/2024
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/